Safety profile of cyclin-dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: a systematic review and meta-analysis

The cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) represent the current standard of care as first- or second-line treatment for patients with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer, demonstrating improved survival outcomes compared to endocrine therapy (ET) alone [1 –3]. Moreover, both abemaciclib and ribociclib, when combined with ET, have demonstrated a significant improvement in invasive disease-free survival in patients with HR+/HER2- early breast cancer who are at high risk of recurrence [4].

Source: Cancer Treatment Reviews - June 15, 2023 Category: Cancer & Oncology Authors: Carlotta Becherini, Luca Visani, Saverio Caini, Indrani S. Bhattacharya, Anna M. Kirby, Gustavo Nader Marta, Gilberto Morgan, Viola Salvestrini, Charlotte E. Coles, Javier Cortes, Giuseppe Curigliano, Evandro de Azambuja, Nadia Harbeck, Clare M. Isacke, O Tags: Systematic or Meta-analysis Studies Source Type: research